^
    Back
    Association details:
    Biomarker:LDH-L
    Cancer:Uveal Melanoma
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    PLoS One
    Title:

    Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

    Excerpt:
    The 1-year OS rate was higher in patients with a LDH level < 2xULN (33% vs. 5%, p<0.0001; Fig. 3A), in patients who received four ipilimumab doses (36% vs. 5%, p<0.0001; Fig. 3B)…
    DOI:
    10.1371/journal.pone.0118564
    Trial ID:
    DeCOG